Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6 ...
When I was diagnosed with lung cancer, I didn’t want to receive chemotherapy, especially when I was a good candidate for ...
Discover a breakthrough imaging technique aimed at improving treatment outcomes for patients with locally advanced ...
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
Ana Baramidze, MD, PhD, discussed 5-year follow-up results from the EMPOWER-Lung study evaluating cemiplimab vs chemotherapy ...
We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent ...
A new series of proteolytic targeting chimeras (PROTACs) was designed by Zhejiang University of Technology scientists based ...
CUT-Tag is used to identify super-enhancers (SEs) for the first time in gastric cancer, and the mRNA decay mechanism activated by SE-driven ZFP36L1 in infiltrative gastric cancer along with innovative ...
GlobalData on MSN2d
Transgene’s stock drops after Phase II cancer jab trial misses primary endpointDespite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback